Associate Director, Clinical Operations Study Lead

## Associate Director, Clinical Operations Study Lead Apply remote type:
OnSitelocations:
MA-Cambridge time type:
Full time posted on:
Posted 3 Days Agojob requisition :
JR2

Blue Rock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company pioneering a new generation of cellular medicines. Utilizing our proprietary CELL+GENETM platform, we direct cellular differentiation and genetically engineer cells to create transformative therapies for patients suffering from neurological and ophthalmological diseases.
Founded in 2016, Blue Rock is at the forefront of the convergence of cell biology and genetic engineering. Our mission is to harness pluripotent stem cell technology and gene editing to deliver authentic, functional cell therapies that address the root causes of disease and offer hope to millions of patients worldwide.
What Are We Doing?
Our foundational science enables the generation and directed differentiation of universal pluripotent stem cells into authentic, functional cells for allogeneic cellular therapies.
We are passionate about realizing the promise of cell and gene therapy, shaping the future of regenerative medicine, and delivering new therapies to patients with limited or no treatment options.
** Who is Blue Rock?
** Blue Rock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company pioneering a new generation of cellular medicines. Utilizing our proprietary
** CELL+GENETM platform**, we direct cellular differentiation and genetically engineer cells to create transformative therapies for patients suffering from neurological and ophthalmological diseases.

Founded in 2016, Blue Rock is at the forefront of the convergence of cell biology and genetic engineering. Our mission is to harness pluripotent stem cell technology and gene editing to deliver authentic, functional cell therapies that address the root causes of disease and offer hope to millions of patients worldwide.
** What Are We Doing?
** Our foundational science enables the generation and directed differentiation of universal pluripotent stem cells into authentic, functional cells for allogeneic cellular therapies.

We are passionate about realizing the promise of cell and gene therapy, shaping the future of regenerative medicine, and delivering new therapies to patients with limited or no treatment options.
** Our Pipeline Vision:
**** Neurology
* * Blue Rock is advancing an innovative pipeline of cell therapies in neurology, focused on addressing the urgent needs of patients with neurodegenerative and neurological disorders. Our lead neurology program,
** bemdaneprocel (DA01)**, is a first-in-class, allogeneic cell therapy designed to replace lost dopaminergic neurons in patients with Parkinson’s disease. This program is currently in phase 3 development with the exPDite-2 clinical trial ongoing in the US, Canada, and Australia.  Additional neurology pipeline assets, including
** DA02
* * and
** MG0X**, are in research phase targeting other high-impact neurological conditions. Our goal is to restore function, slow or halt disease progression, and transform the standard of care for patients with debilitating neurological diseases.
** Ophthalmology
* * Blue Rock is expanding its innovative cell therapy portfolio into ophthalmology, with a focus on addressing unmet medical needs in retinal diseases. Our lead ophthalmology program,
** OpCT
001**, is a first-in-class, allogeneic cell therapy candidate designed to replace lost or damaged retinal pigment epithelial (RPE) cells in patients with advanced retinal disorders, such as geographic atrophy secondary to age-related macular degeneration (AMD). OpCT
001 leverages our CELL+GENETM platform to generate authentic, functional RPE cells from pluripotent stem cells, with the goal of restoring vision and halting disease progression.

Blue Rock is committed to scientific excellence, operational rigor, and the highest standards of ethics and compliance. The company fosters an inclusive, collaborative environment where innovation, diversity, and patient-centricity drive…